Hematology-Oncology Grand Rounds

Antibody-Medicated Thrombotic Syndromes


Thomas L. Ortel, MD, PhD
Professor of Medicine and Professor of Pathology
Department of Medicine
Division of Hematology
Duke University Medical Center

Thomas L. Ortel, MD, PhD is a professor of medicine and pathology and the Director for Laboratory Research in the Department of Medicine at Duke University Medical Center in Durham, North Carolina. He is also the Medical Director of the Anticoagulation Management Service and the Director of the Duke Clinical Coagulation and Platelet Antibody Laboratories. Dr. Ortel received his medical degree and PhD from the Indiana University School of Medicine in Indianapolis and completed residency in internal medicine and a fellowship in hematology/oncology at Duke University Medical Center.  Dr. Ortel has authored or co-authored articles in journals including New England Journal of Medicine, Blood, Journal of Thrombosis and Haemostasis, and Nature. He is currently the principal investigator (PI) for a large National Heart, Lung, and Blood Institute–funded clinical research trial investigating the use of low molecular weight heparin as a bridge in patients on chronic oral anticoagulation for atrial fibrillation (BRIDGE) and is also the PI for one of 2 surveillance programs supported by the Centers for Disease Control and Prevention.

At the conclusion of this program, the participants should be able to:

• Understand clinical presentation and management of antiphospholipid syndrome and MIT
• Discuss the role of the laboratory to diagnose APS and MIT
• Understand new strategies to characterize the genetic risk for complex thrombotic disorders


Date & Time: 
Friday, November 16, 2012 - 8:00am to 9:00am
6051 UC Medical Sciences Building (MSB)
Contact Person: 
Jo Quivers
Contact Email: